Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ERIS.NS
HoldPremium GrowerEris Lifesciences Limited · Healthcare · India · $1.9B · Avg Vol: $1M/d
55
StockRankGet insider-trade alerts
Q
62
V
32
M
56
P/E (TTM)
28.5x
ROE
15.9%
D/E
0.6x
Dividend %
0.5%
COMPANY DESCRIPTION
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.6B | 19.9B | 28.8B | 31.1B | 23.3% | 32.2B | 35.1B | 40.2B | 13.6% |
| EPS (INR) | 28.10 | 28.82 | 25.85 | 45.33 | 17.3% | 47.05 | 42.47 | 56.38 | 11.5% |
| Shares | 136.0M | 136.0M | 136.2M | 138.5M | +1.9% | 138.6M | — | — | — |
| Debt | 8.8B | 27.8B | 24.8B | 23.6B | 39.1% | 23.7B | — | — | — |
| Equity | 22.0B | 25.9B | 28.5B | 39.0B | 21.1% | — | — | — | — |
| Op CF | 2.9B | 4.9B | 10.7B | 5.4B | 22.6% | 5.4B | — | — | — |
| Inv CF | -9.8B | -18.5B | -799.7M | -3.7B | — | — | — | — | — |
| Fin CF | 6.9B | 13.8B | -8.8B | -3.1B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-2.9%
SMA 50SMA 200
Close
$13.99
RSI (14)
54.4
52W High
$18.38
From 52W High
0.8%
SCORE BREAKDOWN
Quality
62
ROIC
16.0%85.2
ROE
15.9%83.5
GP/Assets
32.1%67.1
Op. Margin
25.8%89.0
FCF/Assets
3.3%61.6
Piotroski
549.3
Int. Cover
4.4x50.3
D/E Ratio
0.61x24.7
Current Ratio
0.74x4.6
Value
32
P/E (TTM)
28.5x42.0
EV/EBITDA
18.2x38.3
P/FCF
76.4x19.2
P/B
4.7x30.9
P/S
5.8x38.0
Div Yield
0.5%16.7
Momentum
56
52W High %
76%59.2
RS 6M
4%68.1
SMA 50/200
0.98x51.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+23%36.8
Q Growth
21%55.7
FUNDAMENTALS
Market Cap
$1.9B
P/E (Forward)
23.1x
Gross Margin
73.5%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ERIS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ERIS.NS | Eris Lifesciences Limited(you) | $1.9B | 55 | Hold |
| JUBLPHARMA.NS | Jubilant Pharmova Limited | $1.7B | 60 | Hold |
| PPLPHARMA.NS | Piramal Pharma Limited | $3.2B | 58 | Hold |
| SHILPAMED.NS | Shilpa Medicare Limited | $2.0B | 69 | Buy |
| WOCKPHARMA.NS | Wockhardt Limited | $3.8B | 54 | Hold |
| SUDEEPPHRM.NS | Sudeep Pharma Limited | $1.6B | 41 | Hold |
| NEULANDLAB.NS | Neuland Laboratories Limited | $3.2B | 64 | Hold |
| COHANCE.NS | Cohance Lifesciences Limited | $1.8B | 37 | Hold |
| NATCOPHARM.NS | NATCO Pharma Limited | $1.6B | 72 | Buy |
| ASTRAZEN.NS | AstraZeneca Pharma India Limited | $1.8B | 30 | Sell |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%